VEGFA and metastatic neoplasm: Eight inhibitors that block the vascular endothelial growth factor (VEGF) pathway have now beenapproved as first- or second-line treatment in twelve different late-stage cancer types, thusvalidating antiangiogenesis as a therapeutic modality in treating established metastatic disease andlate-stage glioblastoma (Jayson et al, 2012).